A Study to Assess the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Advanced Basal Cell Carcinoma (BCC)

NCT02371967 · clinicaltrials.gov ↗

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Basal Cell Carcinoma

Interventions

DRUG: Vismodegib

Sponsor

Hoffmann-La Roche